Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

Taxotere(R) (docetaxel) is a registered trademark of Aventis Pharma S.A. Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Company.

CONTACT: investors, Martin Braendle, Director, Investor Relations &Corporate Communications, +49 (0)89 8565 2693, , orLaurie Doyle, Director, Investor Relations & Corporate Communications,+1-609-524-5884, , both of GPC Biotech AG; orBreanna Burkart, +1-720-564-9144, or Anna Sussman, +1-720-564-9143,Directors, Investor Relations and Corporate Communications, PharmionCorporation, ; or media, Brian Hudspith of Maitland, +44(0)20 7379 5151, , or David Schull of RussoPartners, LLC, +1-212-845-4271, , both forGPC Biotech; or Tara May of Pharmion, +1-303-646-7832 ir@gpc-biotech.com usinvestors@gpc-biotech.com ir@pharmion.com bhudspith@maitland.co.uk david.schull@russopartnersllc.com

Web site: http://www.pharmion.com/http://www.gpc-biotech.com/

Ticker Symbol: (NASDAQ-NMS:PHRM),(NASDAQ-NMS:GPCB)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 1Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 2Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 4Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 5AMT Appoints New Chief Executive Officer 58224 1AMT Appoints New Chief Executive Officer 58224 2AMT Appoints New Chief Executive Officer 58224 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 1ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 2ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 4